Literature DB >> 5309487

Influenza immunization: clinical studies with ether-split subunit vaccines.

F B Brandon, F Cox, E Quinn, E A Timm, I W McLean.   

Abstract

Clinical studies of ether-split influenza antigen vaccines have been in progress for almost a decade. One series of such studies, completed before the Hong Kong virus appeared, compared identically constituted conventional and antigen vaccines for serological effectiveness in 1700 vaccinees from the staff of a metropolitan hospital. A series of 6 annual trials included both "old" subjects (vaccinated the previous year) and "new" subjects (no vaccination the previous year). The serological response to the type A2 component of the antigen vaccines was 3-4 times better than that to intact virus in both the old and new populations. The response to either vaccine by new subjects significantly exceeded the response by the old subjects. The type B component of both vaccines induced an equivalent response in both populations. Monovalent Hong Kong vaccines, both conventional and antigen, given just prior to the Hong Kong epidemic induced an anamnestic response in a geriatric group. No influenza-like disease was seen in this high-risk group during the epidemic.

Mesh:

Substances:

Year:  1969        PMID: 5309487      PMCID: PMC2427697     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS.

Authors:  F M DAVENPORT; A V HENNESSY; F M BRANDON; R G WEBSTER; C D BARRETT; G O LEASE
Journal:  J Lab Clin Med       Date:  1964-01

2.  Human febrile response to influenza virus or its ether isolated hemagglutinins.

Authors:  F B Brandon; C D Barrett; A E Hook; G O Lease
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

3.  Structure of the influenza virus; the relation between biological activity and chemical structure of virus fractions.

Authors:  L HOYLE
Journal:  J Hyg (Lond)       Date:  1952-06

4.  Influenza immunization. A new vaccine.

Authors:  H A Cromwell; F B Brandon; I W McLean; J F Sadusk
Journal:  JAMA       Date:  1969-11-24       Impact factor: 56.272

5.  Respiratory virus vaccines. 3. Some biological properties of Sephadex-purified ether-extracted influenza virus antigens.

Authors:  F B Brandon; F Cox; G O Lease; E A Timm; E Quinn; I W McLean
Journal:  J Immunol       Date:  1967-04       Impact factor: 5.422

6.  Relative antigenic potency in man of polyvalent influenza virus vaccines containing isolated hemagglutinins or intact viruses.

Authors:  A V Hennessy; F M Davenport
Journal:  J Immunol       Date:  1966-08       Impact factor: 5.422

7.  ANTIBODY RESPONSE OF HUMAN BEINGS FOLLOWING VACCINATION WITH INFLUENZA VIRUSES.

Authors:  G K Hirst; E R Rickard; L Whitman; F L Horsfall
Journal:  J Exp Med       Date:  1942-05-01       Impact factor: 14.307

  7 in total
  5 in total

1.  Developing vaccines against pandemic influenza.

Authors:  J M Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  Inactivated influenza vaccine efficacy: diminished antigenicity of split-product vaccines in mice.

Authors:  D W Barry; E Staton; R E Mayner
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

3.  Safety and immunogenicity of a paediatric presentation of an influenza vaccine.

Authors:  M Gonzalez; M C Pirez; E Ward; H Dibarboure; A García; H Picolet
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

4.  Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.

Authors:  Barbara J Jester; Timothy M Uyeki; Daniel B Jernigan
Journal:  Am J Public Health       Date:  2020-05       Impact factor: 9.308

Review 5.  Purified viral neuraminidase vaccine to control influenza.

Authors:  D J Arora
Journal:  Can Med Assoc J       Date:  1979-12-22       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.